This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 29, 2015
Genea Biocells Builds Stem-Cell Facility in California
Author(s)BioPharm International Editors
Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.
Advertisement
Australian stem cell company Genea Biocells is expanding its operations to the US with the opening of a new facility in San Diego, California. The office and laboratory space in the Torrey Pines Science Park will accommodate the company's cell and culture media manufacturing, research services, and R&D, and is expected to be fully operational by September 2015.
The new site will house over $2 million worth of equipment, including robotics and instrumentation for high-throughput/high-content screening, all of which is instrumental to the company's chemical biology approach and the research services it provides. Genea Biocells' vice-presidents of chemistry and of business development are already based in the US; the company will retain a small team of scientists in Sydney, primarily for the derivation and banking of new human pluripotent stem cell lines.
"The new facility not only places us directly into our main market, the USA, but also in the midst of one of the largest biotechnology clusters in the world," Genea Biocells general manager, Uli Schmidt, said in a press release. "Being in California also offers a new range of funding opportunities that we will explore to support our R&D programs on neuromuscular diseases."
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5